Biogen News and Research

RSS
ALS Association announces research funds to further understand genetic cause of ALS

ALS Association announces research funds to further understand genetic cause of ALS

OPTIMISE project to collect data that provides in-depth picture of MS experiences

OPTIMISE project to collect data that provides in-depth picture of MS experiences

Phenotyping human diseases in mice: an interview with Professor Carola Vinuesa

Phenotyping human diseases in mice: an interview with Professor Carola Vinuesa

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Living with multiple sclerosis (MS): an interview with Gretchen Rubin and Megan Weigel

Living with multiple sclerosis (MS): an interview with Gretchen Rubin and Megan Weigel

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Pfenex reports total revenue of $3.3 million for second quarter 2014

Pfenex reports total revenue of $3.3 million for second quarter 2014

New MS treatment found safe, tolerable in phase I clinical trials

New MS treatment found safe, tolerable in phase I clinical trials

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

New ebook provides essential insights into Pharma compliance

New ebook provides essential insights into Pharma compliance

Now, hospitals can safely contain HCAI with Howorth Air Technology's BioSphere

Now, hospitals can safely contain HCAI with Howorth Air Technology's BioSphere

Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme

Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme

RBCC's injectable technology poised to improve use of addiction treatment drug

RBCC's injectable technology poised to improve use of addiction treatment drug

Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1

Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1

RBCC’s BiO Assay wins grant from CASIS for Biological Research in Microgravity

RBCC’s BiO Assay wins grant from CASIS for Biological Research in Microgravity

TPP wins $500,000 grant from Biogen Idec to help students start and run own businesses

TPP wins $500,000 grant from Biogen Idec to help students start and run own businesses

Pharmaceutical and academic leaders come together to discuss biomarkers in ALS

Pharmaceutical and academic leaders come together to discuss biomarkers in ALS

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014